Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Versus Postponed Supplementary Parenteral Nutrition After Major Emergency Abdominal Surgery
NCT06089551Phase 4Active, not recruiting
- Sponsor
- Rigshospitalet
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of SmofKabiven Peripheral in Malnutrition (2 arms), sponsored by Rigshospitalet. Primary endpoint: Infectious complications during admission. Started Oct 2023; status: active, not recruiting.
02
Drugs
SmofKabiven Peripheral
03
Conditions
Malnutrition
Beyond the preview
Go deeper on NCT06089551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06089551.